^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

vadacabtagene leraleucel (JCAR015)

i
Other names: JCAR015, anti-CD19-CD28-zeta modified CAR CD3+ T lymphocyte therapy, 19-28z T cells, Autologous T cells genetically targeted to the B cell specific antigen CD19
Associations
Company:
BMS, Memorial Sloan-Kettering Cancer Center
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
Associations
6ms
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=23, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
Trial completion date • Trial primary completion date
|
KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
|
cyclophosphamide • vadacabtagene leraleucel (JCAR015)
6ms
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
Trial completion date • Trial primary completion date
|
cytarabine • etoposide IV • carmustine • melphalan • Neulasta (pegfilgrastim) • vadacabtagene leraleucel (JCAR015)
9ms
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov)
P1, N=93, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
Trial completion date • Trial primary completion date
|
vadacabtagene leraleucel (JCAR015)
over1year
Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov)
P1/2, N=50, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
Trial completion date • Trial primary completion date
|
cyclophosphamide • vadacabtagene leraleucel (JCAR015)
over1year
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
Trial completion date • Trial primary completion date
|
cytarabine • etoposide IV • carmustine • melphalan • Neulasta (pegfilgrastim) • vadacabtagene leraleucel (JCAR015)
almost2years
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov)
P1, N=93, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule)
|
vadacabtagene leraleucel (JCAR015)
almost2years
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=23, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2023 --> May 2024
Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
|
MLL rearrangement • IKZF1 deletion
|
cyclophosphamide • vadacabtagene leraleucel (JCAR015)
2years
Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov)
P1/2, N=50, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule)
|
cyclophosphamide • vadacabtagene leraleucel (JCAR015)
over2years
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Apr 2022 --> Apr 2023
Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule)
|
cytarabine • etoposide IV • carmustine • melphalan • Neulasta (pegfilgrastim) • vadacabtagene leraleucel (JCAR015)
almost3years
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov)
P1, N=93, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Jan 2022 --> Jan 2023
Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule)
|
vadacabtagene leraleucel (JCAR015)
almost3years
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=23, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2022 --> May 2023 | Trial primary completion date: May 2022 --> May 2023
Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
|
MLL rearrangement • IKZF1 deletion
|
cyclophosphamide • vadacabtagene leraleucel (JCAR015)
almost3years
Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov)
P1/2, N=50, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule)
|
cyclophosphamide • vadacabtagene leraleucel (JCAR015)
over3years
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=23, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2021 --> May 2022 | Trial primary completion date: May 2021 --> May 2022
Clinical • Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
|
MLL rearrangement • IKZF1 deletion
|
vadacabtagene leraleucel (JCAR015)
over3years
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2021 --> Apr 2022
Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule)
|
cytarabine • etoposide IV • carmustine • melphalan • Neulasta (pegfilgrastim) • vadacabtagene leraleucel (JCAR015)
almost4years
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov)
P1, N=93, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule)
|
vadacabtagene leraleucel (JCAR015)
over4years
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=23, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2020 --> May 2021 | Trial primary completion date: May 2020 --> May 2021
Clinical • Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
|
MLL rearrangement • IKZF1 deletion
|
vadacabtagene leraleucel (JCAR015)